BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

165 related articles for article (PubMed ID: 28178396)

  • 1. Immunological evaluation of peptide vaccination for cancer patients with the HLA -A11
    Sakamoto S; Matsueda S; Takamori S; Toh U; Noguchi M; Yutani S; Yamada A; Shichijo S; Yamada T; Suekane S; Kawano K; Naitou M; Sasada T; Hattori N; Kohno N; Itoh K
    Cancer Sci; 2017 Apr; 108(4):598-603. PubMed ID: 28178396
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Immunological evaluation of peptide vaccination for cancer patients with the HLA-A26 allele.
    Sakamoto S; Matsueda S; Takamori S; Toh U; Noguchi M; Yutani S; Yamada A; Shichijo S; Yamada T; Suekane S; Kawano K; Sasada T; Hattori N; Kohno N; Itoh K
    Cancer Sci; 2015 Oct; 106(10):1257-63. PubMed ID: 26212219
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Identification of peptide vaccine candidates sharing among HLA-A3+, -A11+, -A31+, and -A33+ cancer patients.
    Takedatsu H; Shichijo S; Katagiri K; Sawamizu H; Sata M; Itoh K
    Clin Cancer Res; 2004 Feb; 10(3):1112-20. PubMed ID: 14871991
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Phase II study of personalized peptide vaccination for refractory bone and soft tissue sarcoma patients.
    Takahashi R; Ishibashi Y; Hiraoka K; Matsueda S; Kawano K; Kawahara A; Kage M; Ohshima K; Yamanaka R; Shichijo S; Shirouzu K; Itoh K; Sasada T
    Cancer Sci; 2013 Oct; 104(10):1285-94. PubMed ID: 23829867
    [TBL] [Abstract][Full Text] [Related]  

  • 5. A new epitope peptide derived from hepatitis C virus 1b possessing the capacity to induce cytotoxic T-lymphocytes in HCV1b-infected patients with HLA-A11, -A31, and -A33.
    Matsueda S; Yamada A; Takao Y; Tamura M; Komatsu N; Yutani S; Ide T; Sata M; Itoh K
    Cancer Immunol Immunother; 2007 Sep; 56(9):1359-66. PubMed ID: 17265020
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Identification of peptide vaccine candidates for prostate cancer patients with HLA-A3 supertype alleles.
    Matsueda S; Takedatsu H; Yao A; Tanaka M; Noguchi M; Itoh K; Harada M
    Clin Cancer Res; 2005 Oct; 11(19 Pt 1):6933-43. PubMed ID: 16203785
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Phase II Study of Personalized Peptide Vaccination with Both a Hepatitis C Virus-Derived Peptide and Peptides from Tumor-Associated Antigens for the Treatment of HCV-Positive Advanced Hepatocellular Carcinoma Patients.
    Yutani S; Ueshima K; Abe K; Ishiguro A; Eguchi J; Matsueda S; Komatsu N; Shichijo S; Yamada A; Itoh K; Sasada T; Kudo M; Noguchi M
    J Immunol Res; 2015; 2015():473909. PubMed ID: 26539554
    [TBL] [Abstract][Full Text] [Related]  

  • 8. New peptide vaccine candidates for epithelial cancer patients with HLA-A3 supertype alleles.
    Matsueda S; Takedatsu H; Sasada T; Azuma K; Ishihara Y; Komohara Y; Noguchi M; Shichijo S; Itoh K; Harada M
    J Immunother; 2007 Apr; 30(3):274-81. PubMed ID: 17414318
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Capability of SART3(109-118) peptide to induce cytotoxic T lymphocytes from prostate cancer patients with HLA class I-A11, -A31 and -A33 alleles.
    Mohamed ER; Naito M; Terasaki Y; Niu Y; Gohara S; Komatsu N; Shichijo S; Itoh K; Noguchi M
    Int J Oncol; 2009 Feb; 34(2):529-36. PubMed ID: 19148489
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Ran, a small GTPase gene, encodes cytotoxic T lymphocyte (CTL) epitopes capable of inducing HLA-A33-restricted and tumor-reactive CTLs in cancer patients.
    Azuma K; Sasada T; Takedatsu H; Shomura H; Koga M; Maeda Y; Yao A; Hirai T; Takabayashi A; Shichijo S; Itoh K
    Clin Cancer Res; 2004 Oct; 10(19):6695-702. PubMed ID: 15475460
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Phase II study of personalized peptide vaccination for previously treated advanced colorectal cancer.
    Kibe S; Yutani S; Motoyama S; Nomura T; Tanaka N; Kawahara A; Yamaguchi T; Matsueda S; Komatsu N; Miura M; Hinai Y; Hattori S; Yamada A; Kage M; Itoh K; Akagi Y; Sasada T
    Cancer Immunol Res; 2014 Dec; 2(12):1154-62. PubMed ID: 25351849
    [TBL] [Abstract][Full Text] [Related]  

  • 12. A novel breast/ovarian cancer peptide vaccine platform that promotes specific type-1 but not Treg/Tr1-type responses.
    Karkada M; Weir GM; Quinton T; Sammatur L; MacDonald LD; Grant A; Liwski R; Juskevicius R; Sinnathamby G; Philip R; Mansour M
    J Immunother; 2010 Apr; 33(3):250-61. PubMed ID: 20445345
    [TBL] [Abstract][Full Text] [Related]  

  • 13. A phase I study of personalized peptide vaccination using 14 kinds of vaccine in combination with low-dose estramustine in HLA-A24-positive patients with castration-resistant prostate cancer.
    Noguchi M; Uemura H; Naito S; Akaza H; Yamada A; Itoh K
    Prostate; 2011 Apr; 71(5):470-9. PubMed ID: 20878951
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Immunological evaluation of personalized peptide vaccination for patients with histologically unfavorable carcinoma of unknown primary site.
    Sakamoto S; Yutani S; Shichijo S; Morita M; Yamada A; Itoh K; Noguchi M
    Cancer Immunol Immunother; 2016 Oct; 65(10):1223-31. PubMed ID: 27549314
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Formulation and characterization of a ten-peptide single-vial vaccine, EP-2101, designed to induce cytotoxic T-lymphocyte responses for cancer immunotherapy.
    Beebe M; Qin M; Moi M; Wu S; Heiati H; Walker L; Newman M; Fikes J; Ishioka GY
    Hum Vaccin; 2008; 4(3):210-8. PubMed ID: 18382135
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Long-term Vaccination with Multiple Peptides Derived from Cancer-Testis Antigens Can Maintain a Specific T-cell Response and Achieve Disease Stability in Advanced Biliary Tract Cancer.
    Aruga A; Takeshita N; Kotera Y; Okuyama R; Matsushita N; Ohta T; Takeda K; Yamamoto M
    Clin Cancer Res; 2013 Apr; 19(8):2224-31. PubMed ID: 23479678
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Feasibility study of personalized peptide vaccination for metastatic recurrent triple-negative breast cancer patients.
    Takahashi R; Toh U; Iwakuma N; Takenaka M; Otsuka H; Furukawa M; Fujii T; Seki N; Kawahara A; Kage M; Matsueda S; Akagi Y; Yamada A; Itoh K; Sasada T
    Breast Cancer Res; 2014 Jul; 16(4):R70. PubMed ID: 24992895
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Recognition of an antigenic peptide derived from tyrosinase-related protein-2 by CTL in the context of HLA-A31 and -A33.
    Wang RF; Johnston SL; Southwood S; Sette A; Rosenberg SA
    J Immunol; 1998 Jan; 160(2):890-7. PubMed ID: 9551926
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Personalized peptide vaccination for cervical cancer patients who have received prior platinum-based chemotherapy.
    Kawano K; Tsuda N; Waki K; Matsueda S; Hata Y; Ushijima K; Itoh K; Yamada A; Kamura T
    Cancer Sci; 2015 Sep; 106(9):1111-7. PubMed ID: 26122553
    [TBL] [Abstract][Full Text] [Related]  

  • 20. An HLA-directed molecular and bioinformatics approach identifies new HLA-A11 HIV-1 subtype E cytotoxic T lymphocyte epitopes in HIV-1-infected Thais.
    Bond KB; Sriwanthana B; Hodge TW; De Groot AS; Mastro TD; Young NL; Promadej N; Altman JD; Limpakarnjanarat K; McNicholl JM
    AIDS Res Hum Retroviruses; 2001 May; 17(8):703-17. PubMed ID: 11429111
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.